Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop ’genetic blueprint’ to predict response to esophageal cancer treatments

20.04.2005


For the first time, researchers appear to be able to use a comprehensive panel of genetic variants to predict how a patient with esophageal cancer will respond to a spectrum of cancer treatments.



At the annual meeting of the American Association for Cancer Research (AACR), researchers from The University of Texas M. D. Anderson Cancer Center report that six different gene variants can predict an improved outcome in patients treated with two different chemotherapy drugs and/or with radiation therapy.

For example, the researchers say that a combination of several gene variants in patients treated with one type of chemotherapy (5-FU) more than doubled survival to 51 months, compared to 25 months in patients treated with the same drug who did not have these variants.


They say the findings represent a leap forward in the goal to provide tailored therapy to individual patients because it offers a genetic blueprint for gauging the potential effectiveness of all common esophageal cancer treatment, not just an analysis of how one or two "candidate" genes respond to a single treatment.

"Our data strongly suggest that combined pathway-based analysis may provide powerful clinical outcome predictors for esophageal cancer as well as for other cancers," says the study’s lead author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology.

"This points to a promising new direction for cancer pharmacogenetics," she says. "Our hope is to have a gene chip one day that can analyze a patient’s genetic makeup and help physicians predict response to a wide variety of therapeutic drugs before treatment even begins."

Esophageal cancer is highly aggressive; approximately 14,520 new esophageal cancer cases and 13,570 associated deaths are expected in 2005, according to the American Cancer Society. Almost half of new cases are diagnosed at an advanced stage, when the five-year survival rate is just 14 percent. Surgery is offered to most patients, as well as one or all of the following treatments - an anti-metabolite chemotherapy agent (5FU), an alkylating agent (cisplatin) and radiation treatment.

Knowing that variations exist in how a person biologically processes those therapies, the researchers collected tissue samples from 210 esophageal cancer patients. They then developed a "pathway analysis" that examined variants in 40 different genes believed to be involved in metabolism, DNA damage repair activity and action of these of therapies. Next, they compared differences in gene variants with outcomes in patients.

"This was like putting together a recipe, searching for different ingredients that work well together for patients," Wu says.

They found that patients with the best outcomes were those who had gene variants that were less effective at neutralizing the killing power of the cancer treatments. Conversely, patients whose genes efficiently counteracted chemotherapy and radiation treatment had shorter survival times overall.

Findings include:

  • For 5FU treatment, patients who had two different variants (AC and AA) in the MTHFR gene pathway that metabolizes folate, the drug’s active ingredient, had significantly improved survival (a median of 51 months) and a longer time to recurrence (36 months) compared to patients with the AA genotype (25 months and 17 months, respectively). "That makes sense because the AC and AA variant genes are less effective in metabolizing folate, which enables the drug to work better," Wu says.
  • Significantly reduced recurrence rates and improved survival also were seen in patients treated with cisplatin who had particular variants of a multi-drug resistance gene (MDR). Proteins produced by this gene prevent cisplatin from entering cancer cells, and variants of the gene (CT and TT) that are less effective at doing so provide more therapeutic benefit to patients, Wu says. Patients with CT variant had a median survival of 29 months and those with a TT variant survived an average of 42 months. On the other hand, patients with the CC variant survived an average of just 17 months.
  • The same pattern held true in analyzing genetic response to radiation treatment. Patients who had inherited less effective variants of a base excision repair gene (XRCC1) that repairs DNA damage from radiation exhibited longer survival. Those with the GG variant had a median survival of more than 57 months, compared to almost 23 months for patients with a GA variant and only 14 months for those with an AA variant.

The researchers also discovered an additive effect between these genes and others that conferred smaller advantages. The higher the number of beneficial variants the patient had, the longer survival was, they found.

As promising as the study is, significant hurdles remain before these findings can be incorporated into treatment, Wu says. Because more data are needed to support their findings, the investigators are accumulating a cohort of 800 esophageal patients from which they can draw a comprehensive genetic profile using blood samples.

If successful, such pathway-based analyses can be conducted for the wide variety of cancers that are treated with 5FU, cisplatin and radiation, as well as other drug treatments, Wu says.

Nancy Jensen | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>